Regeneron Pharmaceuticals Inc. [REGN] Is Currently -2.41 below its 200 Period Moving Avg: What Dose This Mean?

Regeneron Pharmaceuticals Inc. [NASDAQ: REGN] plunged by -$13.83 during the normal trading session on Wednesday and reaching a high of $589.7668 during the day while it closed the day at $559.78.

Regeneron Pharmaceuticals Inc. stock has also loss -0.96% of its value over the past 7 days. However, REGN stock has declined by -8.11% in the 3 months of the year. Over the past six months meanwhile, it has gained 12.71% and gained 49.08% year-on date.

The market cap for REGN stock reached $57.84 billion, with 109.60 million shares outstanding and 101.66 million shares in the current float. Compared to the average trading volume of 717.13K shares, REGN reached a trading volume of 2154992 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Regeneron Pharmaceuticals Inc. [REGN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for REGN shares is $674.63 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on REGN stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Benchmark Company have made an estimate for Regeneron Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 20, 2020. While these analysts kept the previous recommendation, SunTrust raised their target price from $400 to $750. The new note on the price target was released on July 09, 2020, representing the official price target for Regeneron Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $559 to $734, while Wells Fargo kept a Overweight rating on REGN stock. On April 28, 2020, analysts increased their price target for REGN shares from 540 to 575.

The Average True Range (ATR) for Regeneron Pharmaceuticals Inc. is set at 19.11, with the Price to Sales ratio for REGN stock in the period of the last 12 months amounting to 7.23. The Price to Book ratio for the last quarter was 6.77, with the Price to Cash per share for the same quarter was set at 30.43. Price to Free Cash Flow for REGN in the course of the last twelve months was 23.85 with Quick ratio for the last quarter at 1.80.

REGN stock trade performance evaluation

Regeneron Pharmaceuticals Inc. [REGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.96. With this latest performance, REGN shares dropped by -9.70% in over the last four-week period, additionally plugging by 12.71% over the last 6 months – not to mention a rise of 102.47% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for REGN stock in for the last two-week period is set at 42.16, with the RSI for the last a single of trading hit 42.97, and the three-weeks RSI is set at 43.93 for Regeneron Pharmaceuticals Inc. [REGN]. The present Moving Average for the last 50 days of trading for this stock 598.81, while it was recorded at 567.37 for the last single week of trading, and 521.26 for the last 200 days.

Regeneron Pharmaceuticals Inc. [REGN]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Regeneron Pharmaceuticals Inc. [REGN] shares currently have an operating margin of +28.10 and a Gross Margin at +87.38. Regeneron Pharmaceuticals Inc.’s Net Margin is presently recorded at +26.91.

Return on Total Capital for REGN is now 20.78, given the latest momentum, and Return on Invested Capital for the company is 19.90. Return on Equity for this stock inclined to 21.32, with Return on Assets sitting at 15.94. When it comes to the capital structure of this company, Regeneron Pharmaceuticals Inc. [REGN] has a Total Debt to Total Equity ratio set at 6.44. Additionally, REGN Total Debt to Total Capital is recorded at 6.05, with Total Debt to Total Assets ending up at 4.82. Long-Term Debt to Equity for the company is recorded at 6.44, with the Long-Term Debt to Total Capital now at 6.05.

Reflecting on the efficiency of the workforce at the company, Regeneron Pharmaceuticals Inc. [REGN] managed to generate an average of $261,210 per employee. Receivables Turnover for the company is 3.20 with a Total Asset Turnover recorded at a value of 0.59.Regeneron Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.10.

Earnings per share (EPS) analysis for Regeneron Pharmaceuticals Inc. [REGN] stock

With the latest financial reports released by the company, Regeneron Pharmaceuticals Inc. posted 6.67/share EPS, while the average EPS was predicted by analysts to be reported at 6.36/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for REGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Regeneron Pharmaceuticals Inc. go to 12.18%.

Regeneron Pharmaceuticals Inc. [REGN]: Insider Ownership positions

There are presently around $51,705 million, or 90.00% of REGN stock, in the hands of institutional investors. The top three institutional holders of REGN stocks are: FMR LLC with ownership of 12,463,480, which is approximately 47.247% of the company’s market cap and around 0.90% of the total institutional ownership; BLACKROCK INC., holding 9,789,573 shares of the stock with an approximate value of $5.48 billion in REGN stocks shares; and VANGUARD GROUP INC, currently with $4.39 billion in REGN stock with ownership of nearly 22.287% of the company’s market capitalization.

Positions in Regeneron Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 577 institutional holders increased their position in Regeneron Pharmaceuticals Inc. [NASDAQ:REGN] by around 20,341,153 shares. Additionally, 313 investors decreased positions by around 3,700,344 shares, while 104 investors held positions by with 68,325,295 shares. The mentioned changes placed institutional holdings at 92,366,792 shares, according to the latest SEC report filing. REGN stock had 197 new institutional investments in for a total of 1,246,700 shares, while 72 institutional investors sold positions of 382,768 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam